These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 16025585)

  • 21. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
    Hu YQ; Liu YJ
    Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of P-glycoprotein and proliferative index in advanced low grade serous ovarian carcinomas.
    Raspollini MR; Amunni G; Villanucci A; Baroni G; Boddi V; Taddei GL
    J Chemother; 2003 Aug; 15(4):380-6. PubMed ID: 12962367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma lysophosphatidic acid concentration and ovarian cancer.
    Baker DL; Morrison P; Miller B; Riely CA; Tolley B; Westermann AM; Bonfrer JM; Bais E; Moolenaar WH; Tigyi G
    JAMA; 2002 Jun; 287(23):3081-2. PubMed ID: 12069669
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
    Vartiainen J; Lassus H; Lehtovirta P; Finne P; Alfthan H; Butzow R; Stenman UH
    Int J Cancer; 2008 May; 122(9):2125-9. PubMed ID: 18098286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment.
    Brugghe J; Baak JP; Wiltshaw E; Brinkhuis M; Meijer GA; Fisher C
    Gynecol Oncol; 1998 Jan; 68(1):47-53. PubMed ID: 9454660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
    Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
    Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
    Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
    Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells.
    Imai A; Furui T; Tamaya T; Mills GB
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3370-5. PubMed ID: 10999836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells.
    Ren J; Xiao YJ; Singh LS; Zhao X; Zhao Z; Feng L; Rose TM; Prestwich GD; Xu Y
    Cancer Res; 2006 Mar; 66(6):3006-14. PubMed ID: 16540649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.
    Landen CN; Lin YG; Immaneni A; Deavers MT; Merritt WM; Spannuth WA; Bodurka DC; Gershenson DM; Brinkley WR; Sood AK
    Clin Cancer Res; 2007 Jul; 13(14):4098-104. PubMed ID: 17634535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression of connexin 43 in ovarian cancer and its relationship with chemoresistance].
    Li X; Liao QP
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):50-5. PubMed ID: 19563063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lysophosphatidic acid and ovarian cancer: a paradigm for tumorogenesis and patient management.
    Erickson JR; Hasegawa Y; Fang X; Eder A; Mao M; Furui T; Aoki J; Morris A; Mills GB
    Prostaglandins Other Lipid Mediat; 2001 Apr; 64(1-4):63-81. PubMed ID: 11324708
    [No Abstract]   [Full Text] [Related]  

  • 33. The dire need to develop a clinically validated screening method for the detection of early-stage ovarian cancer.
    Dutta S; Wang FQ; Fishman DA
    Biomark Med; 2010 Jun; 4(3):437-9. PubMed ID: 20550476
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic factors in ovarian cancer: how close are we to a complete picture?
    Agarwal R; Kaye SB
    Ann Oncol; 2005 Jan; 16(1):4-6. PubMed ID: 15598928
    [No Abstract]   [Full Text] [Related]  

  • 35. The histology and histogenesis of ovarian neoplasia.
    Woodruff JD; TeLinde RW
    Cancer; 1976 Jul; 38(1 SUPPL):411-3. PubMed ID: 1277099
    [No Abstract]   [Full Text] [Related]  

  • 36. LPAAT-beta identifies aggressive ovarian cancer.
    Burton A
    Lancet Oncol; 2006 Nov; 7(11):893. PubMed ID: 17106955
    [No Abstract]   [Full Text] [Related]  

  • 37. Intracellular lysophosphatidic acid influences cell migration.
    Stöber R
    Arch Toxicol; 2017 Dec; 91(12):4027-4028. PubMed ID: 29170807
    [No Abstract]   [Full Text] [Related]  

  • 38. Lysophosphatidic acid: friend or foe of the ovarian surface epithelium.
    Park DJ; Martyn KD; Warn-Cramer BJ
    Hawaii Med J; 2005 Jun; 64(6):164-5, 169. PubMed ID: 16025585
    [No Abstract]   [Full Text] [Related]  

  • 39. [Ca 125 in epithelial ovarian cancers of FIGO stage I].
    Nagele F; Kurz C; Vavra N; Sevelda P
    Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():291-2. PubMed ID: 8118320
    [No Abstract]   [Full Text] [Related]  

  • 40. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo.
    Kim KS; Sengupta S; Berk M; Kwak YG; Escobar PF; Belinson J; Mok SC; Xu Y
    Cancer Res; 2006 Aug; 66(16):7983-90. PubMed ID: 16912173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.